Shanghai Kehua Bio-Engineering Co Ltd (002022) - Net Assets
Based on the latest financial reports, Shanghai Kehua Bio-Engineering Co Ltd (002022) has net assets worth CN¥3.05 Billion CNY (≈ $446.40 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.55 Billion ≈ $665.33 Million USD) and total liabilities (CN¥1.50 Billion ≈ $218.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Shanghai Kehua Bio-Engineering Co Ltd (002022) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.05 Billion |
| % of Total Assets | 67.1% |
| Annual Growth Rate | 14.14% |
| 5-Year Change | -39.4% |
| 10-Year Change | 63.6% |
| Growth Volatility | 30.14 |
Shanghai Kehua Bio-Engineering Co Ltd - Net Assets Trend (2001–2025)
This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Shanghai Kehua Bio-Engineering Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Shanghai Kehua Bio-Engineering Co Ltd (2001–2025)
The table below shows the annual net assets of Shanghai Kehua Bio-Engineering Co Ltd from 2001 to 2025. For live market cap and overall valuation, see Shanghai Kehua Bio-Engineering Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.11 Billion ≈ $455.03 Million |
-21.92% |
| 2024-12-31 | CN¥3.98 Billion ≈ $582.75 Million |
-20.10% |
| 2023-12-31 | CN¥4.98 Billion ≈ $729.35 Million |
-14.83% |
| 2022-12-31 | CN¥5.85 Billion ≈ $856.33 Million |
+14.05% |
| 2021-12-31 | CN¥5.13 Billion ≈ $750.87 Million |
+31.60% |
| 2020-12-31 | CN¥3.90 Billion ≈ $570.55 Million |
+44.92% |
| 2019-12-31 | CN¥2.69 Billion ≈ $393.70 Million |
+10.72% |
| 2018-12-31 | CN¥2.43 Billion ≈ $355.59 Million |
+16.88% |
| 2017-12-31 | CN¥2.08 Billion ≈ $304.24 Million |
+9.39% |
| 2016-12-31 | CN¥1.90 Billion ≈ $278.14 Million |
+10.15% |
| 2015-12-31 | CN¥1.73 Billion ≈ $252.51 Million |
+36.13% |
| 2014-12-31 | CN¥1.27 Billion ≈ $185.50 Million |
+4.93% |
| 2013-12-31 | CN¥1.21 Billion ≈ $176.79 Million |
+11.20% |
| 2012-12-31 | CN¥1.09 Billion ≈ $158.98 Million |
+5.90% |
| 2011-12-31 | CN¥1.03 Billion ≈ $150.12 Million |
+10.15% |
| 2010-12-31 | CN¥931.34 Million ≈ $136.28 Million |
+17.47% |
| 2009-12-31 | CN¥792.82 Million ≈ $116.01 Million |
+23.16% |
| 2008-12-31 | CN¥643.75 Million ≈ $94.20 Million |
+32.33% |
| 2007-12-31 | CN¥486.48 Million ≈ $71.19 Million |
+22.23% |
| 2006-12-31 | CN¥398.02 Million ≈ $58.24 Million |
+4.55% |
| 2005-12-31 | CN¥380.71 Million ≈ $55.71 Million |
-0.29% |
| 2004-12-31 | CN¥381.82 Million ≈ $55.87 Million |
+140.25% |
| 2003-12-31 | CN¥158.92 Million ≈ $23.26 Million |
+8.70% |
| 2002-12-31 | CN¥146.21 Million ≈ $21.39 Million |
+12.50% |
| 2001-12-31 | CN¥129.97 Million ≈ $19.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Kehua Bio-Engineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12568.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.71 Billion | 64.84% |
| Other Components | CN¥927.57 Million | 35.16% |
| Total Equity | CN¥2.64 Billion | 100.00% |
Shanghai Kehua Bio-Engineering Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Kehua Bio-Engineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Plastika Kritis S.A.
AT:PLAKR
|
$407.95 Million |
|
Forward Air Corporation
NASDAQ:FWRD
|
$407.96 Million |
|
Kenmec Mechanical Engineering Co Ltd
TWO:6125
|
$408.01 Million |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
$408.04 Million |
|
Samhi Hotels Limited
NSE:SAMHI
|
$407.91 Million |
|
Biglari Holdings Inc
NYSE:BH-A
|
$407.89 Million |
|
Holcim Argentina SA
BA:HARG
|
$407.85 Million |
|
Moura Dubeux Engenharia S.A
SA:MDNE3
|
$407.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Kehua Bio-Engineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,349,826,403 to 2,637,914,841, a change of -711,911,562 (-21.3%).
- Net loss of 732,140,994 reduced equity.
- Dividend payments of 15,445,516 reduced retained earnings.
- Other factors increased equity by 35,674,948.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-732.14 Million | -27.75% |
| Dividends Paid | CN¥15.45 Million | -0.59% |
| Other Changes | CN¥35.67 Million | +1.35% |
| Total Change | CN¥- | -21.25% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Kehua Bio-Engineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 34.02x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.16 | CN¥5.42 | x |
| 2002-12-31 | CN¥0.18 | CN¥5.42 | x |
| 2003-12-31 | CN¥0.31 | CN¥5.42 | x |
| 2004-12-31 | CN¥1.04 | CN¥5.42 | x |
| 2005-12-31 | CN¥1.13 | CN¥5.42 | x |
| 2006-12-31 | CN¥1.14 | CN¥5.42 | x |
| 2007-12-31 | CN¥0.92 | CN¥5.42 | x |
| 2008-12-31 | CN¥1.23 | CN¥5.42 | x |
| 2009-12-31 | CN¥1.53 | CN¥5.42 | x |
| 2010-12-31 | CN¥1.84 | CN¥5.42 | x |
| 2011-12-31 | CN¥1.99 | CN¥5.42 | x |
| 2012-12-31 | CN¥2.07 | CN¥5.42 | x |
| 2013-12-31 | CN¥2.30 | CN¥5.42 | x |
| 2014-12-31 | CN¥2.54 | CN¥5.42 | x |
| 2015-12-31 | CN¥3.31 | CN¥5.42 | x |
| 2016-12-31 | CN¥3.60 | CN¥5.42 | x |
| 2017-12-31 | CN¥3.89 | CN¥5.42 | x |
| 2018-12-31 | CN¥4.24 | CN¥5.42 | x |
| 2019-12-31 | CN¥4.59 | CN¥5.42 | x |
| 2020-12-31 | CN¥6.13 | CN¥5.42 | x |
| 2021-12-31 | CN¥7.28 | CN¥5.42 | x |
| 2022-12-31 | CN¥9.03 | CN¥5.42 | x |
| 2023-12-31 | CN¥7.83 | CN¥5.42 | x |
| 2024-12-31 | CN¥6.63 | CN¥5.42 | x |
| 2025-12-31 | CN¥5.13 | CN¥5.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Kehua Bio-Engineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.58%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.76x
- Recent ROE (-27.75%) is below the historical average (16.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 31.96% | 19.86% | 0.79x | 2.04x | CN¥17.99 Million |
| 2002 | 35.32% | 18.44% | 0.77x | 2.50x | CN¥22.86 Million |
| 2003 | 35.67% | 16.46% | 0.90x | 2.41x | CN¥25.70 Million |
| 2004 | 12.84% | 17.92% | 0.54x | 1.33x | CN¥9.48 Million |
| 2005 | 16.56% | 18.77% | 0.66x | 1.34x | CN¥22.35 Million |
| 2006 | 19.85% | 21.99% | 0.70x | 1.29x | CN¥37.01 Million |
| 2007 | 25.70% | 29.57% | 0.65x | 1.33x | CN¥72.08 Million |
| 2008 | 27.02% | 34.09% | 0.66x | 1.20x | CN¥104.61 Million |
| 2009 | 27.04% | 32.90% | 0.67x | 1.23x | CN¥128.78 Million |
| 2010 | 25.04% | 28.83% | 0.72x | 1.21x | CN¥135.30 Million |
| 2011 | 23.17% | 25.95% | 0.73x | 1.23x | CN¥128.88 Million |
| 2012 | 23.49% | 23.66% | 0.79x | 1.26x | CN¥137.72 Million |
| 2013 | 25.47% | 25.87% | 0.81x | 1.21x | CN¥175.11 Million |
| 2014 | 23.23% | 23.97% | 0.85x | 1.14x | CN¥166.30 Million |
| 2015 | 12.58% | 18.22% | 0.56x | 1.24x | CN¥43.22 Million |
| 2016 | 12.60% | 16.64% | 0.60x | 1.26x | CN¥47.92 Million |
| 2017 | 10.90% | 13.66% | 0.59x | 1.36x | CN¥18.01 Million |
| 2018 | 9.54% | 10.44% | 0.57x | 1.61x | CN¥-9.94 Million |
| 2019 | 8.59% | 8.39% | 0.65x | 1.57x | CN¥-33.24 Million |
| 2020 | 21.50% | 16.25% | 0.70x | 1.90x | CN¥361.26 Million |
| 2021 | 21.96% | 17.52% | 0.70x | 1.80x | CN¥463.17 Million |
| 2022 | 20.18% | 13.94% | 0.79x | 1.83x | CN¥490.07 Million |
| 2023 | -5.81% | -9.64% | 0.36x | 1.69x | CN¥-636.98 Million |
| 2024 | -19.12% | -36.41% | 0.34x | 1.56x | CN¥-975.58 Million |
| 2025 | -27.75% | -44.58% | 0.35x | 1.76x | CN¥-995.93 Million |
Industry Comparison
This section compares Shanghai Kehua Bio-Engineering Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,310,265,310
- Average return on equity (ROE) among peers: 18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | CN¥3.05 Billion | 31.96% | 0.49x | $407.94 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $12.65 Billion | 14.27% | 0.24x | $4.04 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $2.68 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $115.39 Million | 30.85% | 0.16x | $519.22 Million |
| Lepu Medical Tech Beijing (300003) | $2.07 Billion | 19.87% | 0.08x | $3.54 Billion |
| INKON Life Technology Co Ltd (300143) | $785.85 Million | 7.49% | 0.06x | $848.83 Million |
| Edan Instruments Inc (300206) | $1.16 Billion | 1.16% | 0.17x | $1.05 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.03 Billion | 33.51% | 0.56x | $596.68 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.80 Billion | 0.85% | 0.07x | $483.21 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $1.36 Billion |
About Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more